Aoxing Pharmaceutical Company Announces Management Change

          Aoxing Pharmaceutical Company Announces Management Change

PR Newswire

JERSEY CITY, N.J., July 6, 2012

JERSEY CITY, N.J., July 6, 2012 /PRNewswire/ -- Aoxing Pharmaceutical Company,
Inc. (NYSEAMEX: AXN), a specialty pharmaceutical company specializing in
research, development, manufacturing and distribution of a range of narcotics
and pain-management products, today announced that Mr. Bob Yunjun Ai has
resigned as Chief Financial Officer of the Company to pursue other business
interests, effective as of July 1, 2012. The Company expresses its
appreciation for Mr. Ai's significant contributions to the Company and wishes
him the best in his future endeavors.

The Company has appointed Mr. Guoan Zhang as acting Chief Financial Officer to
replace Mr. Ai. Mr. Zhangwas Senior Vice President of Finance prior to the
appointment. He joined the Company in 1998 and held various positions in the
finance function. Mr. Zhang is a China CPA.

The Company also appointed Ms. Guirong Zhou as Vice President of R&D to lead
the R&D function. Ms. Zhou has in depth experience in pharmaceuticalresearch
and is responsible for our new drugs applications.Ms. Zhou has around 30
years of research and product development experience and she obtained a lot of
awards and achievements in the pharmaceutical area. Ms. Zhou is a
pharmaceutical expert in research centers and had worked for Shijiazhuang
Pharmaceutical Group and other major pharmaceutical companies.

About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty
pharmaceutical company with its operations in China, specializing in research,
development, manufacturing and distribution of a variety of narcotics and
pain-management products.

For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements involve risks and uncertainties that may cause actual
results to differ materially from those set forth in these statements. All
forward-looking statements included herein are based upon information
available to the Company as of the date hereof and, except as is expressly
required by the federal securities laws, the Company undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new
information, changed circumstances or future events or for any other reason.
To the extent that any statements made here are not historical, these
statements are essentially forward-looking. The Company uses words and phrases
such as "guidance," "forecasted," "projects," "is expected," "remain
confident," "will" and/or similar expressions to identify forward-looking
statements in this press release. Undue reliance should not be placed on
forward-looking information. The economic, competitive, governmental,
technological and other risk factors identified in the Company's filings with
the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors,"
in the Form 10-K for the year ended June 30, 2011, may cause actual results or
events to differ materially from those described in the forward-looking
statements in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether because of
new information, future events, or otherwise.

Company contact:
Vicky Zhang
646-367-1747
Investor.relations@aoxingpharma.com

SOURCE Aoxing Pharmaceutical Company, Inc.

Website: http://www.aoxingpharma.com